
MISSION hires chief business officer from Medivir
pharmafile | March 19, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | medvir, mission, paul wallace
UK, Cambridge-based cancer biotech MISSION Therapeutics has appointed Dr Paul Wallace as its chief business officer.
Having worked in business development roles within drug discovery companies for nearly 20 years, Wallace was most recently executive VP and head of business development at Medivir, where he was also a member of its management team.
Prior to his roles in business development Wallace had a career in pharma research and undertook his PhD and post-doctoral studies at the University of Cambridge.
Anker Lundemose who is MISSION’s chief executive says: “Paul’s extensive business development experience will be invaluable in helping us find the right strategic partnerships to fully realise the potential of these assets.”
Wallace adds: “I am delighted to be joining the MISSION team at a time when the commercialisation of certain of its assets is an increasingly promising prospect.”






